Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more

Retrosynthesis plans a way to make a target molecule by working backward to simpler precursors and candidate reaction routes. The same planning idea can be applied to pharmaceutical, agrochemical, and flavour and fragrance targets, but a computer-generated route is a proposal—not proof that the chemistry works, scales safely, or makes commercial sense.

What retrosynthesis does

In a forward synthesis, chemists start with materials and carry out reactions to make a target. Retrosynthesis reverses that reasoning: begin with the target molecule, consider transformations that could form it, and work backward toward simpler precursors. The result is one or more candidate routes that can guide experiments and further assessment.

Computer-assisted planning can search chemical knowledge and propose complete pathways. Reviews by Yuning Shen and colleagues in Nature Reviews Methods Primers (2021) and Bartosz A. Grzybowski and colleagues in Nature Reviews Bioengineering (2025) discuss automated or algorithm-assisted synthesis planning. A proposed pathway still needs chemical scrutiny: route generation is not the same as experimental confirmation.

Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

How one planning approach spans three industries

A Chemistry World webinar listing published September 15, 2026, and sponsored by Merck describes an evaluation of SYNTHIA across representative datasets covering drug candidates, crop-protection ingredients, and fragrance compounds. This establishes that targets from all three areas were included in that evaluation; it does not establish that the industries have the same route requirements or that performance is equal across them.

Application area What the cited evaluation listing says What it does not establish
Pharmaceuticals Drug candidates were included among the representative target sets. It provides no verified pharma-specific success rate or comparison with the other sectors.
Agrochemicals Crop-protection ingredients were included among the representative target sets. It provides no verified sector-specific economics, production-volume comparison, or success rate.
Flavours and fragrances Fragrance compounds were included among the representative target sets. It provides no verified sector-specific success rate or comprehensive comparison with the other sectors.

The listing reports that the evaluation used a starting library of 14 million commercially available chemicals and more than 120,000 expert-curated reaction rules. Those figures are reported in vendor-sponsored event copy, not an independently established comparative benchmark. The listing also says the webinar discusses how molecular complexity, chiral centres, and synthetic accessibility affect success, and considers routes of one, two, or three steps from commercial building blocks. It supplies neither numerical success rates nor enough results to rank the industries.

Why a proposed route is only a starting point

A pathway that looks plausible on screen may fail in the lab, depend on unavailable starting materials, or prove unsuitable at scale. Chemists must assess the evidence for each reaction and whether the overall route meets the needs of its intended use. A generated route should not be described as validated, economical, scalable, or manufacturing-ready unless those properties have been established separately.

#1 Best Overall
  • Experimental evidence: Check whether the reactions have been demonstrated for the target and conditions at issue. Evidence that some computer-proposed pathways have been experimentally validated does not validate every generated route.
  • Starting materials: Confirm that proposed precursors can actually be sourced in the required quantities and at acceptable cost. A planning tool’s building-block library is not, by itself, proof of current availability or suitability for procurement.
  • Route quality: Consider the number of steps and how they connect, alongside yield, selectivity, and stereochemical control. A shorter route is not automatically the better route.
  • Scale and process needs: Evaluate robustness, safety, waste, material requirements, and commercial viability for the intended process. A route-planning result alone does not answer these questions.

What matters when evaluating a pharmaceutical route

For pharmaceutical process chemistry, the goal is not merely to find a sequence that could make a molecule. Martin D. Eastgate, Michael A. Schmidt, and Keith R. Fandrick’s 2017 Nature Reviews Chemistry article frames the objective as developing a commercially viable approach to a drug candidate. It identifies molecular complexity as a challenge and discusses synthetic strategy, reaction development, and process development in support of safer, more robust, and more efficient manufacturing.

Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

That context makes route options, convergency, material requirements, and robustness important questions when assessing a pharmaceutical proposal. It does not produce a universal ranking of routes: the best choice depends on the molecule and process evidence. Nor should pharmaceutical criteria be assumed to transfer unchanged to agrochemicals or flavour and fragrance production; the cited sources do not establish such a comparison.

Rank #2

How to read claims about route-planning performance

When a tool or evaluation reports a successful path, check what “success” means and what was actually measured. A route proposed by software, a route judged plausible by an expert, and a route demonstrated experimentally are different outcomes. A manufacturing-ready process is a further claim requiring evidence about scale, safety, robustness, sourcing, and commercial viability.

  • Look for the target-set composition and whether it represents the molecules relevant to your work.
  • Check whether results distinguish proposed routes from experimentally demonstrated ones.
  • Ask whether the analysis reports performance by industry, molecular complexity, stereochemical demands, or route length.
  • Check whether starting-material availability reflects materials you can source, rather than only entries in a software library.

For the 2026 SYNTHIA evaluation, the Chemistry World listing is a sponsored event description. It identifies the sectors, library size, reaction-rule count, and discussion topics, but does not publish a results table or sector-level success rates. Treat it as a description of the webinar’s scope, not independent proof of comparative performance.

Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Support on Ko-Fi

Further reading on retrosynthetic approaches

The Royal Society of Chemistry’s 2018 listing for Biocatalysis in Organic Synthesis: The Retrosynthesis Approach describes a Chapter 11 that compares biocatalytic routes and includes pharmaceutical and agrochemical targets. It is a focused technical resource, not a comprehensive treatment of all three sectors; the cited listing does not establish broad coverage of flavours and fragrances.

Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.

Quick Recap

SaleBestseller No. 1
SaleBestseller No. 2
Organic Chemistry (MasteringChemistry)
Organic Chemistry (MasteringChemistry)
Access Code included
$319.99
SaleBestseller No. 4

Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.